DaVita vs Tenet Healthcare
DVA and THC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DVA and THC compare
Tenet Healthcare is the larger company, worth 1.8 times as much as DaVita ($22.0B against $12.0B).
On earnings, Tenet Healthcare is cheaper: it trades at 7.9× trailing earnings, against 13.8× for DaVita.
DaVita grew revenue faster over the last twelve months (6.4% versus 6.2% for Tenet Healthcare).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DVA | THC |
|---|---|---|
| Size and price | ||
| Market cap | $12.0B | $22.0B |
| Share price | $187.50 | $273.25 |
| Change, 1 year | 48.2% | 30.7% |
| Change, 5 years | 71.5% | 262% |
| Beta (5Y) | 0.39 | 1.15 |
| Employees | 78K | 100K |
| StockData Score | ||
| Total score | 13 | 13 |
| Valuation score | 5 | 5 |
| Growth score | 4 (better) | 3 |
| Performance score | 3 (better) | 1 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.8× | 7.9× (better) |
| P/S | 0.8× (better) | 1.0× |
| P/B | – | 4.0× |
| EV/EBITDA | 8.0× | 5.5× (better) |
| P/FCF | 9.2× | 6.6× (better) |
| PEG | 0.73 | 0.13 (better) |
| FCF yield | 10.8% | 15.1% (better) |
| Fair value | $299.15 | $449.89 |
| Margin of safety | 37.3% | 39.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.4% (better) | 6.2% |
| Revenue growth, 5Y average | 3.4% | 3.9% (better) |
| Net income growth (TTM) | 19.2% | – |
| EPS growth (TTM) | 39.9% | 136% (better) |
| EPS growth, 5Y average | 9.3% | 32.8% (better) |
| Profitability | ||
| Operating margin | 15.0% | 24.4% (better) |
| Net margin | 6.5% | – |
| FCF margin | 9.1% | 15.0% (better) |
| Return on invested capital | 18.1% | 28.2% (better) |
| Financial health | ||
| Debt / equity | – | 2.43 |
| Net debt / EBITDA | 3.63 | 1.68 (better) |
| Interest coverage | – | 6.6× |
| Current ratio | 1.41 | 1.58 (better) |
| Altman Z-score | 1.72 | 2.29 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Buyback yield | 6.1% | 8.2% (better) |
| Shareholder yield | 6.1% | 8.2% (better) |
| Ownership | ||
| Held by institutions | 92.5% | 100% |
| Held by insiders | 58.4% | 0.96% |
| Insider net buying, 12 months | −$454M | −$71.2M (better) |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 19.4% | 2.3% |
Go deeper
- DVA stock overview
- DVA income statement
- DVA valuation and score
- THC stock overview
- THC income statement
- THC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.